Evvy has secured $40 million in an oversubscribed Series B financing round to expand its precision women’s health platform, with a focus on developing vaginal microbiome diagnostics across a broader range of conditions.
Founded by Priyanka Jain, Laine Bruzek and Pita Navarro, Evvy initially launched with an at-home vaginal microbiome test and telehealth offering. The company has since expanded its platform to include new treatments, a clinically validated supplement and an AI-powered advisor developed using its proprietary vaginal microbiome dataset, which Evvy describes as the largest of its kind globally.
The new financing will support the expansion of Evvy’s vaginal microbiome diagnostics into areas including fertility, infections, inflammation, PMOS, endometriosis, perimenopause and HPV progression. The company is seeking to use its growing dataset to identify and validate biomarkers that could inform diagnostics and future care pathways across women’s health.
“Evvy is evolving from a vaginal-health testing and care service into a broader platform for women’s health, leveraging Evvy’s unique and novel dataset on the vaginal microbiome,” said Jain. “We’re using that corpus internally to develop and validate biomarker signatures, starting with areas where there is both patient demand and scientific momentum, such as fertility.”
Evvy reports that 96% of its patients opt into research, providing the company with a growing body of microbiome data that can be used to support product development and investigate potential relationships between microbial patterns, interventions and health outcomes.
The company’s research has already identified distinct bacterial vaginosis subtypes as well as microbial genomes that had not previously been identified. These findings form part of Evvy’s efforts to investigate how vaginal microbiome data could support a wider range of clinical applications.
“The dataset is central to Evvy’s next chapter,” Jain said, noting it has detected bacterial vaginosis subtypes and microbial genomes that were previously unknown. “We want to understand which microbial patterns matter, which interventions are associated with meaningful changes, and where the microbiome can serve as a biomarker for risk or health outcomes.”
The financing will enable Evvy to continue developing and validating these biomarker signatures as it expands beyond vaginal health testing and care into a broader women’s health platform.
Click here for the original news story.
